Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting survivin

Journal of Biomedical Nanotechnology

Volumn 8, Issue 4, 2012, Pages 633-641

  Tian, Hongwei ^a   Liu, Shengyong ^a   Zhang, Junfeng ^a   Zhang, Shuang ^a   Cheng, Lin ^a   Li, Can ^a   Zhang, Xiaomei ^a   Dai, Lixia ^a   Fan, Ping ^a   Dai, Lei ^a   Yan, Nv ^a   Wang, Ruibo ^a   Wei, Yuquan ^a   Deng, Hongxin ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Drug resistance; Liposomes; Non small cell lung cancer; Small interference RNA; Survivin

Indexed keywords

ANGIOGENESIS; APOPTOSIS INDUCTION; APOPTOTIC STIMULI; CANCER CELLS; CHEMOTHERAPEUTIC AGENTS; CISPLATIN; COMBINATION TREATMENTS; DRUG RESISTANCE; HAIRPIN RNA; HIGH CONCENTRATION; IMMUNOHISTOCHEMISTRY; IN-VITRO; IN-VIVO; INHIBITOR OF APOPTOSIS PROTEINS; LOW DOSE; LOW SENSITIVITY; LUNG CANCER; LUNG CANCER CELLS; NON SMALL CELL LUNG CANCER; NUDE MICE; PLASMID ENCODING; POTENTIAL APPLICATIONS; PROLIFERATION AND APOPTOSIS; SMALL INTERFERENCE RNA; SURVIVIN; TUMOR CELLS; TUMOR VOLUMES; TUNEL ASSAY; WESTERN BLOTS;

BIOLOGICAL MATERIALS; CELL DEATH; CELL PROLIFERATION; CHEMOTHERAPY; DISEASES; DNA; LIPOSOMES; PLATINUM COMPOUNDS; RNA; TUMORS;

BIOLOGICAL ORGANS;

CD31 ANTIGEN; CISPLATIN; KI 67 ANTIGEN; PLASMID VECTOR; SHORT HAIRPIN RNA; SURVIVIN; SURVIVIN SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION SYSTEM; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; LOW DRUG DOSE; LUNG CANCER; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN TARGETING; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865130582     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1419     Document Type: Article

References (35)

1. D. C. Altier, Xa receptor EPR-1. FASEB J. 9, 860 (1995).
2. A. Sarela, C. Verbeke, J. Ramsdale, C. Davies, A. Markham, and P. Guillou, Expression of survivin: A novel inhibitor of apoptosis and cell cycle regulatory protein in pancreatic adenocarcinoma. Brit. J. Cancer. 86, 886 (2002).
3. J. R. Kanwar, W. P. Shen, R. K. Kanwar, R. W. Berg, and G. W. Krissansen, Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. 93, 1541 (2001).
4. M. Pennati, G. Colella, M. Folini, L. Citti, M. G. Daidone, and N. Zaffaroni, Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 109, 285 (2002).
5. F. Paduano, R. Villa, M. Pennati, M. Folini, M. Binda, M. G. Daidone, and N. Zaffaroni, Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17- demethoxygeldanamycin in human prostate cancer cells. Mol. Cancer Ther. 5, 179 (2006).
6. G. Jiang, J. Li, Z. Zeng, and L. Xian, Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol. Ther. 5, 435 (2006).
7. V. Pisarev, B. Yu, R. Salup, S. Sherman, D. C. Altieri, and D. I. Gabrilovich, Full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res. 9, 6523 (2003).
8. D. Grossman, P. J. Kim, J. S. Schechner, and D. C. Altieri, Inhibition of melanoma tumor growth in vivo by survivin targeting. P. Natl. Acad. Sci. USA 98, 635 (2001).
9. V. Gebbia, F. Oniga, R. Agueli, and A. Paccagnella, Treatment of advanced non-small cell lung cancer: Chemotherapy with or without cisplatin. Ann. Oncol. 17, 83 (2006).
10. R. Perez, Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 34, 1535 (1998).
11. A. Rossi, P. Maione, and C. Gridelli, Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert. Opin. Drug Saf. 4, 1051 (2005).
12. G. J. Hannon, RNA interference. Nature 418, 244 (2002).
13. S. Pai, Y. Lin, B. Macaes, A. Meneshian, C. Hung, and T. Wu, Prospects of RNA interference therapy for cancer. Gene Ther. 13, 464 (2005).
14. G. J. Hannon and J. J. Rossi, Unlocking the potential of the human genome with RNA interference. Nature 431, 371 (2004).
15. N. S. Templeton, D. D. Lasic, P. M. Frederik, H. H. Strey, D. D. Roberts, and G. N. Pavlakis, Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15, 647 (1997).
16. W. B. Butler, P. J. Berlinski, R. M. Hillman, W. H. Kelsey, and M. M. Toenniges, Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell line MCF-7. Cancer Res. 46, 6339 (1986).
17. P. Loehrer and L. Einhorn, Drugs five years later. Cisplatin. Ann. Intern. Med. 100, 704 (1984).
18. A. Eastman, Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cell. 2, 275 (1990).
19. K. M, Henkels and J. J. Turchi, Induction of apoptosis in cisplatin-sensitive and-resistant human ovarian cancer cell lines. Cancer Res. 57, 4488 (1997).
20. N. Kurihara, T. Kubota, H. Y. Oshiya, Y. Otani, K. Kumai, and M. Kitajima, Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time! Á concentration product against human gastric cancer cell lines in vitro. J. Surg. Oncol. 60, 238 (1995).
21. F. Morazzoni, C. Canevali, M. Zucchetti, S. Caroli, A. Alimonti, F. Petrucci, G. Giudice, E. Masoni, and A. V. Bedini, cis-Diamminedichloroplatinum (II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: A pharmacokinetic approach. J. Cancer Res. Clin. Oncol. 124, 37 (1998).
22. C. Adida, P. L. Crotty, J. McGrath, D. Berrebi, J. Diebold, and D. C. Altieri, Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43 (1998).
23. G. Ambrosini, C. Adida, and D. C. Altieri, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917 (1997).
24. D. Grossman, J. M. Mcniff, F. Li, and D. C. Altieri, Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab. Invest. 79, 1121 (1999).
25. H. Kawasaki, D. C. Altieri, C. D. Lu, M. Toyoda, T. Tenjo, and N. Tanigawa, Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58, 5071 (1998).
26. H. Kojima, M. Iida, Y. Yaguchi, R. Suzuki, N. Hayashi, H. Moriyama, and Y. Manome, Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch. Otolaryngol. 132, 682 (2006).
27. X. Chen, X. Luan, D. Lei, X. Ma, X. Liu, J. Liu, and X. Pan, Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells. J. Oto-Rhino-Laryngol. 70, 168 (2008).
28. R. A. Olie, W. A. P. Simes, B. Baumann, S. H. Leech, D. Fabbro, R. A. Stahel, and U. A. Zangemeister-Wittke, Novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805 (2000).
29. T. Yamamoto, Y. Manome, M. Nakamura, and N. Tanigawa, Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur. J. Cancer. 38, 2316 (2002).
30. I. Tamm, Y. Wang, E. Sausville, D. A. Scudiero, N. Vigna, T. Oltersdorf, and J. C. Reed, IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315 (1998).
31. F. Li, G. Ambrosini, E. Y. Chu, J. Plescia, S. Tognin, P. C. Marchisio, and D. C. Altieri, Control of apoptosis and mitotic spindle checkpoint by survivin. EMBO J. 14, 5258 (1995).
32. F. Andrade, S. Roy, D. Nicholson, N. Thornberry, A. Rosen, and L. Casciola-Rosen, Granzyme B directly and efficiently cleaves several downstream caspase substrates: Implications for CTL-induced apoptosis, Immunity 8, 451 (1998).
33. T. Yu-Cheng and H. Leaf, Self-assembled lipid nanomedicines for siRNA tumor targeting. J. Biomed. Nanotechnol. 5, 351 (2009).
34. E. Jger, C. G. Venturini, F. S. Poletto, L. M. Colomé, J. P. Pohlmann, A. Bernardi, A. M. Battastini, S. S. Guterres, and A. R. Pohlman, Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J. Biomed. Nanotechnol. 5, 130 (2009).
35. S. Foillard, G. Zuber, and E. Doris, Polyethylenimine-carbon nanotube nanohybrids for siRNA-mediated gene silencing at cellular level. Nanoscale 3, 1461 (2011).